CCN2 and neoplasm: Calcipotriol was shown to induce lipid droplet formation in PDAC PSCs, reduce tumor volume and stromal density, improve tumor vascularity, increase intra-tumoral gemcitabine (by 500%), block TGF-β/SMAD signaling and decrease the release of IL-6, CTGF and CXCL12.